232 related articles for article (PubMed ID: 34774527)
1. The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension.
Haddad F; Contrepois K; Amsallem M; Denault AY; Bernardo RJ; Jha A; Taylor S; Arthur Ataam J; Mercier O; Kuznetsova T; Vonk Noordegraaf A; Zamanian RT; Sweatt AJ
Chest; 2022 May; 161(5):1347-1359. PubMed ID: 34774527
[TBL] [Abstract][Full Text] [Related]
2. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children.
Said F; Haarman MG; Roofthooft MTR; Hillege HL; Ploegstra MJ; Berger RMF
J Pediatr; 2020 May; 220():139-145. PubMed ID: 32113658
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Rosenkranz S; Lange TJ
J Heart Lung Transplant; 2022 Jul; 41(7):971-981. PubMed ID: 35430147
[TBL] [Abstract][Full Text] [Related]
4. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
[TBL] [Abstract][Full Text] [Related]
5. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
[TBL] [Abstract][Full Text] [Related]
6. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
[TBL] [Abstract][Full Text] [Related]
7. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.
Simpson CE; Damico RL; Hassoun PM; Martin LJ; Yang J; Nies MK; Vaidya RD; Brandal S; Pauciulo MW; Austin ED; Ivy DD; Nichols WC; Everett AD
Chest; 2020 Jun; 157(6):1606-1616. PubMed ID: 31987881
[TBL] [Abstract][Full Text] [Related]
9. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
[TBL] [Abstract][Full Text] [Related]
10. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
[TBL] [Abstract][Full Text] [Related]
11. Cytokines as prognostic biomarkers in pulmonary arterial hypertension.
Boucly A; Tu L; Guignabert C; Rhodes C; De Groote P; Prévot G; Bergot E; Bourdin A; Beurnier A; Roche A; Jevnikar M; Jaïs X; Montani D; Wilkins MR; Humbert M; Sitbon O; Savale L
Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36549710
[TBL] [Abstract][Full Text] [Related]
12. Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension: Comparison With Validated Models.
Amsallem M; Sweatt AJ; Aymami MC; Kuznetsova T; Selej M; Lu H; Mercier O; Fadel E; Schnittger I; McConnell MV; Rabinovitch M; Zamanian RT; Haddad F
Circ Cardiovasc Imaging; 2017 Jun; 10(6):. PubMed ID: 28592589
[TBL] [Abstract][Full Text] [Related]
13. Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension.
Chang WT; Shih JY; Hong CS; Lin YW; Chen YC; Ho CH; Chen ZC; Roan JN; Hsu CH
ESC Heart Fail; 2021 Aug; 8(4):3082-3092. PubMed ID: 33955184
[TBL] [Abstract][Full Text] [Related]
14. Eye signs as a novel risk predictor in pulmonary arterial hypertension associated with systemic lupus erythematosus.
Li J; Xiong J; Liu P; Peng Y; Cai S; Fang X; Yu S; Zhao J; Wu R
Adv Rheumatol; 2024 Feb; 64(1):15. PubMed ID: 38424650
[TBL] [Abstract][Full Text] [Related]
15. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
[TBL] [Abstract][Full Text] [Related]
16. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
[No Abstract] [Full Text] [Related]
17. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
[TBL] [Abstract][Full Text] [Related]
18. Metabolic profiling of in vivo right ventricular function and exercise performance in pulmonary arterial hypertension.
Simpson CE; Coursen J; Hsu S; Gough EK; Harlan R; Roux A; Aja S; Graham D; Kauffman M; Suresh K; Tedford RJ; Kolb TM; Mathai SC; Hassoun PM; Damico RL
Am J Physiol Lung Cell Mol Physiol; 2023 Jun; 324(6):L836-L848. PubMed ID: 37070742
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension.
Shafran I; Probst V; Panzenböck A; Sadushi-Kolici R; Gerges C; Wolzt M; Segel MJ; Celermajer DS; Lang IM; Skoro-Sajer N
JACC Heart Fail; 2024 Jun; 12(6):1089-1097. PubMed ID: 38573264
[TBL] [Abstract][Full Text] [Related]
20. Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.
Rhodes CJ; Wharton J; Swietlik EM; Harbaum L; Girerd B; Coghlan JG; Lordan J; Church C; Pepke-Zaba J; Toshner M; Wort SJ; Kiely DG; Condliffe R; Lawrie A; Gräf S; Montani D; Boucly A; Sitbon O; Humbert M; Howard LS; Morrell NW; Wilkins MR
Am J Respir Crit Care Med; 2022 May; 205(9):1102-1111. PubMed ID: 35081018
[No Abstract] [Full Text] [Related]
[Next] [New Search]
